Healthcare investors are entering 2026 with renewed momentum, but also with more selective underwriting criteria. Deal formation is improving, particularly in the Americas, and artificial intelligence is playing a larger role in how buyers assess durability of earnings, operational scalability, and margin resilience. Across healthcare M&A, AI is increasingly part of the discussion around operational efficiency, margin expansion, and valuation.
Healthcare and life sciences remain active areas for investment, but buyers are approaching opportunities with greater discipline. Rather than rewarding growth narratives alone, investors are placing more weight on operational execution, margin visibility, and the ability to scale efficiently in a cost-constrained environment. That shift is helping elevate interest in companies that can demonstrate measurable productivity gains and stronger resilience across clinical and administrative functions.
AI shifts from feature to differentiator
This convergence explains why AI has become such a powerful differentiator in healthcare dealmaking. For years, many healthcare companies experimented with AI through pilots or narrow point solutions. Today, investors expect AI to be embedded into core workflows and to deliver measurable results.
The rationale is straightforward. Healthcare organizations remain under pressure from rising labor costs, staffing shortages, reimbursement complexity, and administrative burden. In that environment, buyers are placing a premium on assets that can show repeatable process improvement, stronger visibility into operations, and credible pathways to scale. AI-enabled operating models can support those outcomes when they are embedded in core workflows rather than layered on as isolated tools.
As a result, AI increasingly influences diligence discussions and valuation frameworks. Buyers are examining whether AI is embedded in revenue, workflow, and cost-management functions, whether it can scale after acquisition, and whether it improves execution without adding operational complexity. In that context, AI is less a headline feature than a test of how durable and transferable a company’s operating model may be.
Where investors see the most value today
Investor interest is especially concentrated in areas where AI’s financial impact is immediate and visible. Revenue cycle management (RCM) is a prime example. AI-driven RCM platforms can automate claims processing, flag errors before submission, reduce denials, and accelerate collections. For buyers, that translates directly into improved cash flow and more predictable earnings, two attributes that support stronger multiples.
Clinical documentation is another area drawing significant attention. AI-powered tools can reduce the administrative burden on clinicians while improving documentation quality and compliance. That combination matters in M&A because it supports both margin improvement and workforce stability, two factors that can make or break post-transaction performance.
More broadly, investors are favoring platforms that use AI to create consistency across fragmented operations. Standardized, data-driven workflows make it easier to integrate add-on acquisitions, scale across geographies, and extract synergies, key objectives in today’s platform-driven M&A strategies.
Implications for healthcare M&A in 2026
The acceleration in deal formation suggests that healthcare M&A activity will remain strong the rest of the year. But it will also remain selective. As the gap widens between AI-enabled platforms and those that rely on manual or legacy processes, so too will the gap in valuations.
For sellers, this means being able to clearly articulate how AI supports operational efficiency and margin expansion. For buyers, it means deeper diligence on data infrastructure, interoperability, and governance, not just growth projections. And for the market overall, it means AI will continue to shape not only which deals get done, but how they are structured and priced.
Recent early-stage deal activity points to continued investor interest in healthcare assets with stronger operating leverage and clearer scalability. But the broader takeaway is less about any single dataset and more about where buyer attention is concentrating: businesses that can convert technology adoption into measurable workflow improvement, margin support, and post-close execution. In today’s market, AI is becoming one of several indicators investors use to assess whether an asset can sustain performance through the next phase of consolidation.
Colin Schopbach
Colin Schopbach is America CRO at Datasite.
